A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

BackgroundThis study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy.Patients and methods Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen were given 2.5 mg letrozole once daily and were randomly assigned (2:1) to tipifarnib 300 mg (TL) or placebo (L) twice daily for 21 consecutive days in 28-day cycles. The primary endpoint was objective response rate.ResultsOf 120 patients treated with TL (n = 80) or L (n = 40), 113 were evaluable for response. Objective response rate was 30% (95% CI; 20–41%) for TL and 38% (95% CI; 23–55%) for L. There was no significant difference in response duration, time to disease progression or survival. Clinical benefit rates were 49% (TL) and 62% (L). Tipifarnib was generally well tolerated; a higher incidence of drug-related asymptomatic grade 3/4 neutropenia was observed for TL (18%) than for L (0%). Tipifarnib population pharmacokinetics were similar to previous studies, with no significant difference in trough letrozole concentrations between the TL and L groups. Conclusions Adding tipifarnib to letrozole did not improve objective response rate in this population of patients with advanced breast cancer.

[1]  G. Prendergast,et al.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton , 1994, Molecular and cellular biology.

[2]  C. Der,et al.  Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. , 1996, Oncogene.

[3]  S. Sebti,et al.  GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. , 1997, Cancer research.

[4]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Rosen,et al.  A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells* , 1998, The Journal of Biological Chemistry.

[6]  R. Coffey,et al.  Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.

[8]  G. Prendergast,et al.  Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. , 1999, Cancer research.

[9]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[10]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[11]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[12]  M. Dowsett,et al.  Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[14]  J. Schellens,et al.  Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Dowsett,et al.  Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Nicholson,et al.  The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. , 2003, Endocrinology.

[17]  E. Levin.  Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.

[18]  R. Sutherland,et al.  Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI‐277 on inhibition of MCF‐7 breast cancer cell‐cycle progression , 2003, International journal of cancer.

[19]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[20]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[21]  C. Der,et al.  Aberrant function of the Ras signal transduction pathway in human breast cancer , 1995, Breast Cancer Research and Treatment.

[22]  W. Telford,et al.  Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines , 2003, Breast Cancer Research and Treatment.

[23]  R. Schiff,et al.  Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Johnston.  Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Shiuan Chen,et al.  Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.

[27]  W. Carney,et al.  Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy , 2005, Cancer.

[28]  J. Pérez-Ruixo,et al.  Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. , 2006, British journal of clinical pharmacology.

[29]  M. Dowsett,et al.  The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo , 2007, Molecular Cancer Therapeutics.